AstraZeneca commits $200 million to Tempus AI through 2031 but can walk away for the shortfall
A five-year, $200 million renewal from AstraZeneca gives Tempus AI a revenue floor it can book, filed days before a shareholder vote on a stock-funded acquisition, but the contract lets the drugmaker quit early by paying only the shortfall.
Richard Tangthree-minute read
Tempus AI's+0.49% — Tempus AI, up 0.49 percent today founding pharma partner just signed up for five more years, and kept an exit. An 8-K filed on November 18, 2026, discloses that AstraZeneca has committed $200 million in fees over a renewal term running January 2027 through December 2031: a $40 million annual target, a $32 million minimum in each calendar year, extendable to 2032 if the total comes up short 1.
That is the headline. The clause underneath is the story. Our earlier piece on Tempus's first profitable quarter carried the Personalis timeline and the BMS collaboration; the Fifth Amendment and its convenience clause are what changed since.
The commitment is real, but so is the exit
AstraZeneca "continues to have the right to terminate the MSA for convenience at any time." If it quits before paying the full $200 million, it owes Tempus the shortfall 1. Read plainly: AstraZeneca owes the cash even if it walks, but the amendment cannot keep it as a customer.
Tempus keeps the money and loses its flagship pharma partner, along with the strategic collaborator benefits the deal extends only while it lasts 1.
The floor is small next to what Tempus already books
Scale tells you who wins what. Tempus generated $108.1 million of Data and Applications revenue in the third quarter alone and has booked more than $550 million in data licensing so far this year, including October's BMS collaboration: $137.5 million of oncology licensing plus $55 million for a BMS and Pathos license to its Alzheimer's and dementia data 2.
Two BMS licenses are about a third of Tempus's 2026 data licensing
- BMS oncology licensing, $137.5M137.525%
- BMS and Pathos dementia license, $55M5510%
- All other 2026 licensing, $357.5M357.565%
Data
| Slice | Value | Share |
|---|---|---|
| BMS oncology licensing, $137.5M | 137.5 | 25% |
| BMS and Pathos dementia license, $55M | 55 | 10% |
| All other 2026 licensing, $357.5M | 357.5 | 65% |
The $32 million yearly minimum is a fraction of one quarter of that segment's revenue 12. So the commitment de-risks Tempus's 2027 bookings line without making it dependent, and the concentration risk runs both ways: Tempus loses its largest pharma relationship if AstraZeneca walks, while AstraZeneca holds five years of optionality over an AI data supplier for the price of a shortfall payment 12.
A single quarter of Tempus revenue tops the whole five-year AstraZeneca pledge
Data
| Revenue | |
|---|---|
| Q4 '23 | $0.15B |
| Q1 '24 | $0.15B |
| Q2 '24 | $0.17B |
| Q3 '24 | $0.18B |
| Q4 '24 | $0.2B |
| Q1 '25 | $0.26B |
| Q2 '25 | $0.32B |
| Q3 '25 | $0.33B |
| Q4 '25 | $0.37B |
| Q1 '26 | $0.35B |
| Q2 '26 | $0.38B |
| Q3 '26 | $0.41B |
The filing lands twelve days before the Personalis vote
The filing lands twelve days before Personalis shareholders vote on November 30 to approve Tempus's acquisition of their company, a cash-and-stock merger anchored at $16.25 per Personalis share that a law firm is already investigating over price 23. Tempus is paying partly in its own stock, so anything that supports the quality of its committed revenue touches the currency of the deal.
Whether the amendment actually moves those voters is unproven; what the contract shows is that bookings are now written as a five-year minimum with a make-whole. What to watch next: whether AstraZeneca spends toward its $40 million annual target or drifts to the $32 million floor 1, and how the November 30 meeting prices the difference.
Get Health by email, free
AI in medicine, pharma and biotech. In our daily email, every weekday.






Reader comments
0 comments